Free Trial

Zymeworks (ZYME) Competitors

Zymeworks logo
$15.05 +0.97 (+6.89%)
As of 09/5/2025 04:00 PM Eastern

ZYME vs. KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, MIRM, MLTX, and MTSR

Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry.

Zymeworks vs. Its Competitors

Krystal Biotech (NASDAQ:KRYS) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Krystal Biotech has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Krystal Biotech currently has a consensus target price of $210.38, indicating a potential upside of 40.00%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Zymeworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88
Zymeworks
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 13.7% of Krystal Biotech shares are owned by insiders. Comparatively, 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Krystal Biotech has a net margin of 40.85% compared to Zymeworks' net margin of -59.96%. Krystal Biotech's return on equity of 15.21% beat Zymeworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech40.85% 15.21% 13.81%
Zymeworks -59.96%-21.59%-16.52%

In the previous week, Krystal Biotech had 4 more articles in the media than Zymeworks. MarketBeat recorded 8 mentions for Krystal Biotech and 4 mentions for Zymeworks. Krystal Biotech's average media sentiment score of 1.22 beat Zymeworks' score of -0.07 indicating that Krystal Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zymeworks
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Krystal Biotech has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$290.52M14.97$89.16M$4.9230.54
Zymeworks$76.30M14.83-$122.69M-$0.97-15.52

Summary

Krystal Biotech beats Zymeworks on 14 of the 16 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZYME vs. The Competition

MetricZymeworks IndustryManufacturing SectorNASDAQ Exchange
Market Cap$1.13B$2.37B$2.52B$9.94B
Dividend YieldN/A13.82%2.53%4.53%
P/E Ratio-15.5225.1626.3226.13
Price / Sales14.8316,002.65118.21121.74
Price / CashN/A19.9723.1829.11
Price / Book3.063.4231.486.09
Net Income-$122.69M-$402.94M$16.40M$266.19M
7 Day Performance1.62%0.50%0.45%0.44%
1 Month Performance25.21%1.82%2.59%4.88%
1 Year PerformanceN/A12.76%31.91%26.03%

Zymeworks Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZYME
Zymeworks
0.1069 of 5 stars
$15.05
+6.9%
N/AN/A$1.13B$76.30M-15.52460
KRYS
Krystal Biotech
4.8917 of 5 stars
$150.27
+0.3%
$210.38
+40.0%
-18.4%$4.35B$290.52M30.54210Positive News
PCVX
Vaxcyte
2.7082 of 5 stars
$33.02
+2.7%
$130.00
+293.7%
-70.4%$4.29BN/A-8.03160Positive News
ACAD
ACADIA Pharmaceuticals
4.2183 of 5 stars
$25.26
-0.9%
$28.88
+14.3%
+57.2%$4.26B$957.80M18.99510Positive News
Analyst Downgrade
ACLX
Arcellx
2.6226 of 5 stars
$72.62
+0.6%
$114.31
+57.4%
+1.9%$4.03B$56.98M-21.2380Positive News
ADMA
ADMA Biologics
3.636 of 5 stars
$16.87
-0.2%
$27.67
+64.0%
+3.8%$4.03B$426.45M19.62530Positive News
ARWR
Arrowhead Pharmaceuticals
3.9411 of 5 stars
$29.08
+3.9%
$43.14
+48.4%
+30.9%$4.02B$3.55M-22.72400Trending News
Analyst Forecast
Insider Trade
Analyst Revision
MENS
Jyong Biotech
N/A$52.31
-5.1%
N/AN/A$3.98BN/A0.0031News Coverage
Gap Down
MIRM
Mirum Pharmaceuticals
3.2401 of 5 stars
$76.06
+2.5%
$74.13
-2.5%
+85.0%$3.82B$336.89M-62.86140Positive News
MLTX
MoonLake Immunotherapeutics
2.7467 of 5 stars
$59.44
-0.5%
$74.43
+25.2%
+29.2%$3.82BN/A-21.382High Trading Volume
MTSR
Metsera
N/A$35.87
-1.2%
$59.00
+64.5%
N/A$3.77BN/A0.0081News Coverage
Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ZYME) was last updated on 9/8/2025 by MarketBeat.com Staff
From Our Partners